Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Atopic Dermatitis
Interventions: ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more

Conditions: Ulcerative Colitis
Interventions: Catered diet, Diet guidance sessions, Dietary counseling, Feedback sessions; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 16 Years to 75 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Lacosamide (LCM), Carbamazepine Immediate Release (CBZ-IR); Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Atlanta, Georgia • Overland Park, Kansas

Conditions: Knee Arthritis, Knee Osteoarthritis, Knee Pain Chronic, Knee Discomfort, Rheumatoid Arthritis, Knee Pain Swelling
Interventions: Gold Factor (Gold Nanoparticles, AuNPs), Placebo; Dietary Supplement
Lead sponsor: 4Life Research, LLC; Industry
Eligibility: 18 Years to 87 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Heart Failure With a Preserved Ejection Fraction, Heart Failure, Diastolic, Chronotropic Incompetence
Interventions: Rate adaptive atrial pacing using a dual-chamber pacemaker, Pacemaker system will be implanted but set to Pacing Off.; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Infections, Bacterial
Interventions: Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Type I Diabetes, Pediatrics, Food Insecurity
Interventions: Community Servings, PedsQL Survey, Nutrition Counseling, SDOH Survey; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 5 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Healthy, Enteric Hyperoxaluria
Interventions: SYNB8802, Placebo; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Tucson, Arizona • Tampa, Florida • Knoxville, Tennessee + 1 more

Conditions: Neurofibroma
Interventions: LS11; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 3 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diffuse Large B-cell Lymphoma
Interventions: RICE, GaRD Treatment; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Idiopathic Pulmonary Fibrosis, Cough
Interventions: Thalidomide, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV
Interventions: Treatment Advocacy; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glioblastoma
Interventions: Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine; Drug · Radiation · Biological
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years and older
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more

Conditions: Sleep Apnea, Obstructive
Interventions: Desipramine, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Velcade, Thalidomide, Dexamethasone; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Bladder Cancer
Interventions: Pembrolizumab (MK-3475), Bacillus Calmette-Guérin (BCG); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Suicide Risk, Psychiatric Disorders
Interventions: Treatment as usual (TAU), FSJS, FSJS+Navigator Intervention; Other
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Cardiovascular Disease
Interventions: oral education & written tips for remembering medications, pill box, pocket medication card, sharing information with community pharmacist, Medication use evaluations by community pharmacist, informing physician if patient has stopped a medication, Routine discharge counseling, Letter to physician/discharge summary; Behavioral · Device · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Interventions: Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Epilepsy
Interventions: Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms, Chronic Neutrophilic Leukemia
Interventions: Momelotinib, Azacitidine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Transcranial Direct Current Stimulation, Healthy
Interventions: Transcranial direct current stimulation (tDCS); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 60 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Volunteers
Interventions: Entrectinib Test Formulation (F1), Entrectinib Reference Formulation (F06); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Pregnancy, Unplanned, Sexually Transmitted Diseases
Interventions: About Us; Behavioral
Lead sponsor: ETR Associates; Other
Eligibility: 14 Years to 18 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Oakland, California • San Diego, California • Scotts Valley, California

Search by objective public record fields.

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)

Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

Gold Factor on Knee Joint Health and Function

Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure

Drug-drug Interaction Study of Gepotidacin

Food is Medicine in Pediatric Patients With Diabetes

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas

Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide

Treatment Advocacy Intervention for HIV-Positive African Americans

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A

UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

Improving Mental Health Treatment for Individuals in Crisis Interacting With the Criminal-Legal System

Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

Maximizing the Impact of Neuroplasticity Using Transcranial Electrical Stimulation Study 1

A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants

A Healthy Relationships Program for Vulnerable Youth